374 related articles for article (PubMed ID: 29290251)
1. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
[TBL] [Abstract][Full Text] [Related]
2. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
[TBL] [Abstract][Full Text] [Related]
6. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
7. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
8. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
[TBL] [Abstract][Full Text] [Related]
9. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
10. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
11. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
[TBL] [Abstract][Full Text] [Related]
12. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Puca L; Gavyert K; Sailer V; Conteduca V; Dardenne E; Sigouros M; Isse K; Kearney M; Vosoughi A; Fernandez L; Pan H; Motanagh S; Hess J; Donoghue AJ; Sboner A; Wang Y; Dittamore R; Rickman D; Nanus DM; Tagawa ST; Elemento O; Mosquera JM; Saunders L; Beltran H
Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894499
[TBL] [Abstract][Full Text] [Related]
13. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
14. Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.
Matsuo K; Taniguchi K; Hamamoto H; Inomata Y; Komura K; Tanaka T; Lee SW; Uchiyama K
Cancer Sci; 2021 Aug; 112(8):2984-2992. PubMed ID: 34107132
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
Calvo E; Spira A; Miguel M; Kondo S; Gazzah A; Millward M; Prenen H; Rottey S; Warburton L; Alanko T; Cassier PA; Yoh K; Italiano A; Moreno V; Peltola K; Seto T; Toyozawa R; Afar DE; Englert S; Komarnitsky P; Lambert S; Parikh A; Vosganian G; Gao B
Cancer Treat Res Commun; 2021; 28():100405. PubMed ID: 34329846
[TBL] [Abstract][Full Text] [Related]
16. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.
Lashari BH; Vallatharasu Y; Kolandra L; Hamid M; Uprety D
Drugs R D; 2018 Dec; 18(4):255-258. PubMed ID: 30232719
[TBL] [Abstract][Full Text] [Related]
17. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Hann CL; Burns TF; Dowlati A; Morgensztern D; Ward PJ; Koch MM; Chen C; Ludwig C; Patel M; Nimeiri H; Komarnitsky P; Camidge DR
J Thorac Oncol; 2021 Sep; 16(9):1582-1588. PubMed ID: 34242790
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
[TBL] [Abstract][Full Text] [Related]
19. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Johnson ML; Zvirbule Z; Laktionov K; Helland A; Cho BC; Gutierrez V; Colinet B; Lena H; Wolf M; Gottfried M; Okamoto I; van der Leest C; Rich P; Hung JY; Appenzeller C; Sun Z; Maag D; Luo Y; Nickner C; Vajikova A; Komarnitsky P; Bar J
J Thorac Oncol; 2021 Sep; 16(9):1570-1581. PubMed ID: 33823285
[TBL] [Abstract][Full Text] [Related]
20. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
